145 related articles for article (PubMed ID: 16814645)
1. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial.
Pinto DS; Stone GW; Ellis SG; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Mehran R; Na Y; Turco M; Caputo R; Popma JJ; Cutlip DE; Russell ME; Cohen DJ;
J Am Coll Cardiol; 2006 Jul; 48(1):32-6. PubMed ID: 16814645
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
[TBL] [Abstract][Full Text] [Related]
4. Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial).
Nikolsky E; Kosinski E; Mishkel GJ; Kimmelstiel C; McGarry TF; Mehran R; Leon MB; Russell ME; Ellis SG; Stone GW
Am J Cardiol; 2005 Mar; 95(6):709-15. PubMed ID: 15757595
[TBL] [Abstract][Full Text] [Related]
5. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions.
Wöhrle J; Nusser T; Kestler HA; Kochs M; Hombach V
Clin Res Cardiol; 2007 Feb; 96(2):70-6. PubMed ID: 17146605
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial.
Brilakis ES; Lichtenwalter C; de Lemos JA; Roesle M; Obel O; Haagen D; Saeed B; Gadiparthi C; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S
J Am Coll Cardiol; 2009 Mar; 53(11):919-28. PubMed ID: 19281920
[TBL] [Abstract][Full Text] [Related]
8. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of the platinum chromium TAXUS Element (ION) stent: The PERSEUS Workhorse and Small Vessel trial five-year results.
Kereiakes DJ; Cannon LA; Dauber I; Ball M; Bertolet B; Foster M; Nersesov AY; Underwood PL; Allocco DJ; Dawkins KD
Catheter Cardiovasc Interv; 2015 Nov; 86(6):994-1001. PubMed ID: 25678402
[TBL] [Abstract][Full Text] [Related]
10. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
11. Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events.
Leon MB; Allocco DJ; Dawkins KD; Baim DS
JACC Cardiovasc Interv; 2009 Jun; 2(6):504-12. PubMed ID: 19539253
[TBL] [Abstract][Full Text] [Related]
12. Prevention of lesion recurrence in chronic total coronary occlusions by paclitaxel-eluting stents.
Werner GS; Krack A; Schwarz G; Prochnau D; Betge S; Figulla HR
J Am Coll Cardiol; 2004 Dec; 44(12):2301-6. PubMed ID: 15607390
[TBL] [Abstract][Full Text] [Related]
13. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
Vink MA; Dirksen MT; Suttorp MJ; Tijssen JG; van Etten J; Patterson MS; Slagboom T; Kiemeneij F; Laarman GJ
JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.
Stone GW; Ellis SG; O'Shaughnessy CD; Martin SL; Satler L; McGarry T; Turco MA; Kereiakes DJ; Kelley L; Popma JJ; Russell ME;
JAMA; 2006 Mar; 295(11):1253-63. PubMed ID: 16531618
[TBL] [Abstract][Full Text] [Related]
15. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
[TBL] [Abstract][Full Text] [Related]
16. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
[TBL] [Abstract][Full Text] [Related]
17. Influence of stent length to lesion length ratio on angiographic and clinical outcomes after implantation of bare metal and drug-eluting stents (the TAXUS-IV Study).
Wong SC; Hong MK; Ellis SG; Buchbinder M; Reisman M; DeLago A; Kellett M; Popma JJ; Russell ME; Mehran R; Moses JW; Stone GW
Am J Cardiol; 2005 May; 95(9):1043-8. PubMed ID: 15842968
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.
Kastrati A; Mehilli J; von Beckerath N; Dibra A; Hausleiter J; Pache J; Schühlen H; Schmitt C; Dirschinger J; Schömig A;
JAMA; 2005 Jan; 293(2):165-71. PubMed ID: 15644543
[TBL] [Abstract][Full Text] [Related]
19. Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent.
Garg S; Smith K; Torguson R; Okabe T; Slottow TL; Steinberg DH; Roy P; Xue Z; Gevorkian N; Satler LF; Kent KM; Suddath WO; Pichard AD; Waksman R
Catheter Cardiovasc Interv; 2007 Jul; 70(1):9-14. PubMed ID: 17580367
[TBL] [Abstract][Full Text] [Related]
20. One-year results of the CRISTAL Trial, a randomized comparison of cypher sirolimus-eluting coronary stents versus balloon angioplasty for restenosis of drug-eluting stents.
Chevalier B; Moulichon R; Teiger E; Brunel P; Metzger JP; Pansieri M; Carrie D; Stoll HP; Wittebols K; Spaulding C; Fajadet J;
J Interv Cardiol; 2012 Dec; 25(6):586-95. PubMed ID: 22994863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
